SecProbe.io

United States securities and exchange commission logo
December 12, 2022
Ramzi Haidamus
Chief Executive Officer
PepperLime Health Acquisition Corp
548 Market Street, Suite 97425
San Francisco, CA 94104
Re:PepperLime Health Acquisition Corp
Form 10-K for the fiscal year ended December 31, 2021
Filed March 17, 2022
File No. 001-40915
Dear Ramzi Haidamus:
             We have reviewed your filing and have the following comments.  In some of our
comments, we may ask you to provide us with information so we may better understand your
disclosure.
            Please respond to these comments within ten business days by providing the requested
information or advise us as soon as possible when you will respond.  If you do not believe our
comments apply to your facts and circumstances, please tell us why in your response.
            After reviewing your response to these comments, we may have additional comments.

Form 10-K for the fiscal year ended December 31, 2021
Note 7. Redeemable Class A Ordinary Shares and Shareholders' Deficit, page F-15
1.We note you have classified the 8,100,000 private placements warrants as equity. Please
provide us with your analysis under ASC 815-40 to support your accounting treatment for
these warrants. As part of your analysis, please address whether there are any terms or
provisions in the warrant agreement that provide for potential changes to the settlement
amounts that are dependent upon the characteristics of the holder of the warrant, and if so,
how you analyzed those provisions in accordance with the guidance in ASC 815-40. Your
response should address, but not be limited to, your disclosure that "[i]f the Private
Placement Warrants are held by someone other than the Initial Shareholders or their
permitted transferees, the Private Placement Warrants will be redeemable by the Company
and exercisable by such holders on the same basis as the Public Warrants."

 FirstName LastNameRamzi  Haidamus
 Comapany NamePepperLime Health Acquisition Corp
 December 12, 2022 Page 2
 FirstName LastName
Ramzi  Haidamus
PepperLime Health Acquisition Corp
December 12, 2022
Page 2
General
2.With a view toward disclosure, please tell us whether your sponsor is, is controlled by, or
has substantial ties with a non-U.S. person. If so, please revise your disclosure in future
filings to include disclosure that addresses how this fact could impact your ability to
complete your initial business combination. For instance, discuss the risk to investors that
you may not be able to complete an initial business combination with a U.S. target
company should the transaction be subject to review by a U.S. government entity, such as
the Committee on Foreign Investment in the United States (CFIUS), or ultimately
prohibited. Disclose that as a result, the pool of potential targets with which you could
complete an initial business combination may be limited. Further, disclose that the time
necessary for government review of the transaction or a decision to prohibit the
transaction could prevent you from completing an initial business combination and require
you to liquidate. Disclose the consequences of liquidation to investors, such as the losses
of the investment opportunity in a target company, any price appreciation in the combined
company, and the warrants, which would expire worthless. Please include an example of
your intended disclosure in your response.
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            You may contact Jeffrey Lewis at (202) 551-6216 or Kristi Marrone at (202) 551-3429
with any questions.
Sincerely,
Division of Corporation Finance
Office of Real Estate & Construction